Compare ResMed Inc. (RMD) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 3.6× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| RMD | SGOV | |
|---|---|---|
Market Cap | $31.89B | $114.40B |
Volume | 618,314 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $277.88 | $100.72 |
52-Week Low | $182.82 | $100.28 |
Typical Hold Time | 51 Days | 50 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.515 with minimal daily movement, reflecting its stable nature. The technical picture is bearish according to moving averages, though oscillators are neutral. Recent corporate actions show consistent dividend payments. Market sentiment is influenced by broader bond market volatility and institutional positioning shifts.
The outlook for SGOV is tied to short-term Treasury yields and Federal Reserve policy. Opportunities include stability and income, but risks involve rising interest rates and institutional selling. Investors should weigh the ETF's defensive role against potential yield compression in a changing rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
